APOE and Alzheimer disease: Since it is currently unrealistic to change genetic risk polymorphisms, modifying or treating mediating factors such as CRP by pharmacological and nonpharmacological approaches for genetic risk carriers of APOE ε4, SPI1 rs1057233(AA) and CD33 rs3865444(CC) could be an alternative strategy to prevent or treat AD [70].